Siedlerstraße 7 | 68623 Lampertheim, Germany

info@zamann-pharma.com

The FDA has issued a warning letter to Sanofi’s Genzyme manufacturing facility in Waterford, Ireland, after identifying significant weaknesses in Data Integrity and quality management during an inspection. The agency found deficiencies in laboratory record reviews, traceability, and deviation handling
New analysis suggests that pharmaceutical tariffs alone may not achieve the reshoring goals many policymakers expect. According to legal and industry experts in the United States, the economics of generic drug manufacturing, combined with GMP compliance costs and validation requirements,
Roche has unveiled AXELIOS 1 Sequencing Platform, its next-generation single-molecule sequencing system powered by Sequencing by Expansion (SBX) technology. The platform delivers same-day whole-genome sequencing while combining high accuracy, flexible throughput, and near real-time analysis. The launch reflects the growing
Orca Bio has received FDA approval for Tregzi, the first engineered regulatory T-cell therapy designed to reduce chronic GVHD following allogeneic stem cell transplantation in adults with blood cancers. While the approval marks a major clinical achievement, it also highlights
A U.S. congressional committee has launched an investigation into clinical trial activities conducted by Pfizer and Bristol Myers Squibb in China. Representative John Moolenaar raised concerns about trial sites linked to military-run facilities and regions such as Xinjiang. The inquiry
Zachary Zubulake reports in PharmTech Explained that industry experts Brian Drapeau and Richard Jaenisch analyzed how AI is reshaping GMP workflows while regulators tighten scrutiny on its use in pharmaceutical manufacturing. The discussion highlights a shift in compliance expectations where
The U.S. Food and Drug Administration has approved Viridian Therapeutics’ Lumvoa in the United States for active and chronic thyroid eye disease, expanding treatment options in a previously limited therapeutic area. Announced on June 28, 2026, the decision makes Lumvoa
The U.S. Medicare program will expand coverage of GLP-1 weight-loss medications in July 2026 under the new Bridge initiative, giving seniors with obesity access to semaglutide-based therapies at lower co-pays. The policy aims to improve treatment access for older adults,
Ionis Pharmaceuticals has moved closer to its first fully owned blockbuster drug after the US Food and Drug Administration (FDA) expanded approval for Tryngolza (olezarsen) in severe hypertriglyceridemia (sHTG). The decision strengthens the drug’s commercial trajectory, expands its patient reach
The US Department of Health and Human Services (HHS) has introduced Operation TrialBlazer in Washington, a regulatory blueprint aimed at accelerating early-stage clinical development and narrowing the gap with China’s faster drug discovery timelines. The initiative focuses on simplifying FDA